UroGen Reports Durable JELMYTO Response in Five-Year Follow-Up
UroGen said final results from the Olympus five-year follow-up study reinforce durable response with JELMYTO in patients with low-grade upper tract urothelial cancer.
UroGen said final results from the Olympus five-year follow-up study reinforce durable response with JELMYTO in patients with low-grade upper tract urothelial cancer.